XML 45 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition (Tables) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]        
Net revenue $ 1,273.0 $ 1,053.0 $ 3,515.0 $ 2,810.0
Elimination of revenue attributable to multiple locations (27.0) (24.0) $ (85.0) (68.0)
Revenue Recognition and Deferred Revenue [Abstract]        
Contractual Liabilities     The contract liabilities balance (current and non-current) as of March 31, 2022 and June 30, 2021 are as follows:
(Dollars in millions)
Balance at June 30, 2021$321 
Balance at March 31, 2022$198 
Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:$252 
  
Geographical [Member]        
Disaggregation of Revenue [Line Items]        
Disaggregation of Revenue    
The following table allocates revenue by the location where the goods were made or the service performed:

Three Months Ended  
March 31,		Nine Months Ended  
March 31,
(Dollars in millions)2022202120222021
United States$847 $670 $2,270 $1,722 
Europe3733451,095 955 
Other8062235 201 
Elimination of revenue attributable to multiple locations(27)(24)(85)(68)
Total$1,273 $1,053 $3,515 $2,810 
  
United States        
Disaggregation of Revenue [Line Items]        
Net revenue 847.0 670.0 $ 2,270.0 1,722.0
Europe        
Disaggregation of Revenue [Line Items]        
Net revenue 373.0 345.0 1,095.0 955.0
International Other        
Disaggregation of Revenue [Line Items]        
Net revenue $ 80.0 $ 62.0 $ 235.0 $ 201.0
Product and Service[Member]        
Disaggregation of Revenue [Line Items]        
Disaggregation of Revenue    
The following tables allocate revenue for the three and nine months ended March 31, 2022 and 2021, by type of activity and reporting segment (in millions):
Three Months Ended March 31, 2022BiologicsSoftgel and Oral TechnologiesOral and Specialty DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$200 $280 $90 $— $570 
Development services498 44 64 — 606 
Clinical supply services— — — 101 101 
Total$698 $324 $154 $101 $1,277 
Inter-segment revenue elimination(4)
Combined net revenue$1,273 
Three Months Ended March 31, 2021BiologicsSoftgel and Oral TechnologiesOral and Specialty DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$148 $212 $118 $— $478 
Development services396 32 53 — 481 
Clinical supply services— — — 100 100 
Total$544 $244 $171 $100 $1,059 
Inter-segment revenue elimination(6)
Combined net revenue$1,053 
Nine Months Ended March 31, 2022
BiologicsSoftgel and Oral TechnologiesOral and Specialty DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$503 $776 $274 $— $1,553 
Development services1,379 120 182 — 1,681 
Clinical supply services— — — 296 296 
Total$1,882 $896 $456 $296 $3,530 
Inter-segment revenue elimination(15)
Combined net revenue$3,515 

Nine Months Ended March 31, 2021
BiologicsSoftgel and Oral TechnologiesOral and Specialty DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$362 $616 $335 $— $1,313 
Development services963 95 165 — 1,223 
Clinical supply services— — — 286 286 
Total$1,325 $711 $500 $286 $2,822 
Inter-segment revenue elimination(12)
Combined net revenue$2,810